Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a well-characterized tumour-suppressor gene that is lost or mutated in about half of metastatic castration-resistant prostate cancers and in many other human cancers. The restoration of functional PTEN as a treatment for prostate cancer has, however, proven difficult. Here, we show that PTEN messenger RNA (mRNA) can be reintroduced into PTEN-null prostate cancer cells in vitro and in vivo via its encapsulation in polymerlipid hybrid nanoparticles coated with a polyethylene glycol shell. The nanoparticles are stable in serum, elicit low toxicity and enable high PTEN mRNA transfection in prostate cancer cells. Moreover, significant inhibition of tumour growth is achieved when delivered systemically in multiple mouse models of prostate cancer. We also show that the restoration of PTEN function in PTEN-null prostate cancer cells inhibits the phosphatidylinositol 3-kinase (PI3K)-AKT pathway and enhances apoptosis. Our findings provide proof-of-principle evidence of the restoration of mRNA-based tumour suppression in vivo.
T he onset and maintenance of cancer frequently involves gain of oncogenic function (via the amplification or mutation of oncogenes) along with loss of tumour suppression. PTEN is among the best-characterized tumour suppressors. PTEN mutations have been reported in a variety of human cancers 1 , including prostate cancer (PCa). Loss of one PTEN allele is seen in the majority of localized PCa, and homozygous deletion of PTEN is more common in metastatic castration-resistant PCa (~50%) than in androgen-dependent primary tumours (~10%) [2] [3] [4] [5] [6] [7] [8] . Moreover, loss of PTEN protein expression is more frequent than genomic PTEN loss, and has been correlated with a high Gleason score and faster progression to metastasis 9 . PTEN encodes a dual phosphatase that acts on both lipid and protein substrates. By catalysing phosphatidylinositol (3, 4, 5) -trisphosphate dephosphorylation, PTEN negatively regulates the PI3K-AKT pathway [10] [11] [12] [13] [14] , a key signalling mediator of most receptor tyrosine kinases 15 . Recent integrative genomic profiling and whole-exosome sequencing analyses have highlighted the frequency of alterations of the PI3K-AKT pathway in PCa, which is associated with both primary (42%) and metastatic disease (~100%) 16, 17 . Since activation of the PI3K-AKT pathway upon PTEN loss enhances tumour cell survival, proliferation 12, 18 , migration 19, 20 , angiogenesis 21, 22 and anti-apoptosis 10 , blocking this pathway has been proposed to inhibit tumour growth and to sensitize tumour cells to apoptosis. While pharmacological inhibitors of the AKT-mechanistic target of rapamycin (mTOR) pathway are in clinical development, they cannot fully compensate for the loss of PTEN function and show a poor toxicity profile.
Restoration of PTEN function via plasmid DNA transfection of tumour cells has been demonstrated in vitro 10 ; however, the in vivo delivery of plasmid DNA has been severely hindered by systemic instability. Recently, chemically modified mRNA has emerged as an intriguing alternative to DNA-based gene therapy, as its intrinsic qualities facilitate its ease of use as a genetic material that is independent of nuclear localization and genomic integration for transfection activity 23, 24 . mRNA also provides rapid protein expression even in non-dividing and hard-to-transfect cells (for example, immune cells), as well as cancer cells. Moreover, mRNA offers more consistent and predictable protein expression kinetics than DNA, whose expression kinetics show random onset [25] [26] [27] [28] . However, delivery of mRNA presents several potential challenges, including large size, highly negative charge, susceptibility to degradation and suboptimal protein translation capacity if it is not effectively modified and delivered into cells 29 . Thus, safe and effective in vivo cytosolic delivery of mRNA to tumour cells while retaining integrity and functional activity remains elusive. Many nano-engineered formulations (for example, polymer-based nanoparticles (NPs) 30, 31 , lipidbased NPs [32] [33] [34] [35] and lipidoid NPs 36, 37 ) designed for in vivo delivery of small interfering RNA (siRNA) or other small oligonucleotides have shown promising results in laboratory or clinical settings 23, [38] [39] [40] . However, they might not be efficient for mRNA delivery due to mRNA NPs exhibit low cytotoxicity and potent transfection efficiency in vitro, and protect mRNA activity from RNase degradation. To evaluate in vitro cytotoxicity, PTEN-null PCa (PC3) cells were treated with EGFP-mRNA-PGCP NPs for 16 h and further incubated with fresh culture medium for 24 h. Nearly 80% of PC3 cells were still viable at the highest EGFP mRNA concentration of 0.5 µ g ml -1 (Fig. 2a ). An Alamar Blue toxicity assay was also performed for DU145 and LNCaP cells (two other PCa cell lines). There was no notable reduction in cell viability, maintaining ~90-100% viable cells at various EGFP mRNA concentrations from 0.062 to 0.5 µ g ml -1 in DU145 cells and 100% cell viability at all concentrations in LNCaP cells ( Supplementary Fig. 1a and Supplementary Fig. 2a, respectively) . mRNA NPs. a, Self-assembly process of polymer-lipid hybrid mRNA NPs (i-iv) and schematic representation of NP structure. After self-assembly of cationic G0-C14 with anionic mRNA together with PLGA, the formulated polymer-lipid hybrid core was coated with lipid-PEG (EGFP mRNA was used as the reporter mRNA). b, Agarose gel electrophoresis assay of mRNA stability in organic solvent, naked or complexed with cationic G0-C14, at various weight ratios (from 0.1 to 20). The formulated mRNA PGCP NP was also subjected to gel electrophoresis to detect any mRNA leaching from the NPs. Approximately 0.125 µ g of EGFP mRNA was used for all groups in this assay. c, mRNA-PGCP NPs were characterized with NanoSIGHT to check the size distribution (n = 3 batches, 121.5 ± 2.3 nm) and TEM to observe morphology. A weight ratio of 1:15 for mRNA:G0-C14 was used for the NP preparation. d, Stability of mRNA-PGCP NPs in 10% serum condition at 37 °C was evaluated by measuring particle size changes determined with NanoSIGHT at various time points up to 48 200 0 10 1 10 2 10 3 10 4 10 5 10 6 10 1 10 2 10 3 10 4 10 5 10 6 10 1 10 2 10 3 10 4 10 5 10 6 GFP + 91.6% GFP + 96.3% 10 1 10 2 10 3 10 4 10 5 10 6 10 1 10 2 10 3 10 4 10 5 10 6 10 1 10 2 10 3 10 4 10 5 We next examined transfection efficacy in vitro. The EGFP-mRNA-PGCP NPs mediated highly efficient transfection of PC3 cells, showing a dose-dependent increase of EGFP expression that correlated with increasing EGFP mRNA concentrations (from Cells were treated with various mRNA concentrations (0.062, 0.125, 0.250 or 0.500 µ g ml -1 ) of EGFP-mRNA-PGCP NPs for 16 h and further incubated for 24 h in standard cell culture incubation conditions. a, For the Alamar Blue cytotoxicity assay, cell viability was normalized with the untreated control group. Error bars represent the s.d. (n = 6). b, Transfection efficiency (percentage of GFP-positive cells) was determined using flow cytometry (****P < 0.0001). Error bars represent the s.d. (n = 4) and significance was determined using one-way ANOVA. c, Transfection efficiency was also analysed with the histograms for the respective groups using Flowjo software. d, Fluorescence microscopy images of PC3 cells transfected with naked EGFP mRNA, EGFP-mRNA-PGCP NPs or L2K-EGFP-mRNA (magnification at × 20). e, Mechanism of cellular uptake and endosomal escape of mRNA NPs in PC3 cells. The cells were pre-incubated for 30 min in serum-free medium containing inhibitors (filipin, chlorpromazine (CPZ), EIPA and Baf A1 were used as the inhibitor for caveolae-mediated endocytosis, clathrin-mediated endocytosis, macropinocytosis and intracellular proton-pump effects, respectively) or combinations of inhibitors (filipin, chlorpromazine or EIPA mixed with Baf A1) before transfection with EGFP-mRNA-PGCP NPs at a mRNA concentration of 0.250 μ g ml -1 . Transfection efficiency (percentage of GFP-positive cells) was determined using flow cytometry (***P < 0.001 and ****P < 0.0001). Error bars represent the s.d. (n = 5) and significance was determined using one-way ANOVA. f, The mechanism of cellular uptake and intracellular transport of the hybrid mRNA NPs is schematically illustrated.
0.062 to 0.5 µ g ml -1 ) (Fig. 2b,c) . The transfection efficacy (in terms of percentage of EGFP-positive cells) of the NPs at mRNA concentrations of 0.25 and 0.5 µ g ml -1 was demonstrably greater than that mediated by the commercial transfection agent Lipofectamine mRNA into PC3 cells using L2K to assess its ability to facilitate protein expression, diminish cancer cell viability and suppress the PI3K-AKT pathway. PC3 cells transfected with PTEN mRNA via L2K showed markedly higher HA-PTEN expression than pHAGE-PTEN WT (a MSCV-N-Flag-HA-IRES-PURO Gateway destination vector with long terminal repeat-driven expression of wild-type PTEN), as shown by immunofluorescence staining ( Supplementary  Fig. 4a ). Western blotting also showed that HA-PTEN expression was significantly higher than plasmid PTEN transfection. Furthermore, L2K-transfected PTEN mRNA treatment downregulated the PI3K-AKT pathway, with decreased phosphorylation of 4E-BP1-Ser65, PRAS40-Thr246 and Foxo3a-Ser318/321 as determined by western blotting ( Supplementary Fig. 4b ). Accordingly, L2K PTEN mRNA treatment dramatically decreased cell viability as measured by a CyQUANT assay ( Supplementary Fig. 4c ).
Next, we applied the optimized NP system to determine whether our PTEN-mRNA-PGCP NPs could restore the therapeutic functionality of tumour-suppressor PTEN to PCa cells. Both immunofluorescence staining ( Fig. 3a , and see Supplementary Fig. 5 for brightfield image) and western blotting ( Fig. 3b ) confirmed the restoration of HA-PTEN expression transduced by PTEN-mRNA-PGCP NP treatment. It is worth noting that since PTEN-mRNA-PGCP NP treatment reduced cell viability, the cell density of this group was considerably lower than that of the group treated with control empty PGCP NPs ( Fig. 3a ). Next, PTEN-mRNA-PGCP NP treatment significantly decreased cell viability in a dose-dependent manner compared to both the empty PGCP NP and EGFP-mRNA-PGCP NP groups, as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assays ( Fig. 3c ). We further found that after 48 h of treatment, PTEN-mRNA-PGCP NPs efficiently inhibited PI3K-AKT signalling, as indicated by the greater decrease in phosphorylation of AKT-Ser473, p70S6K-Thr389, 4E-BP1-Thr37/46, PRAS40-Thr246 and Foxo3a-Ser318/321. PTEN-mRNA-PGCP NP treatment also further reduced the basal phosphorylation of the above proteins under serum-starvation conditions (Fig. 3b ). Moreover, early apoptosis was increased after treatment with PTEN-mRNA-PGCP NPs, as indicated by elevated numbers of Annexin V-positive cells via flow cytometry ( Fig. 3d ). An approximately four-fold increase in cell death was noted in PC3 cells after PTEN-mRNA-PGCP NP treatment relative to control empty PGCP NPs. We also noted a slight increase in apoptosis in the EGFP-mRNA-PGCP NP-treated group; this was in part a possible consequence of inducing exogenous RNA in PC3 cells. However, this effect was modest in comparison to the increase in apoptosis observed with the PTEN-mRNA-PGCP NP group. These results indicate that our hybrid NP system has the potential to effectively deliver PTEN mRNA and to restore functional PTEN activity to tumour cells.
Consistent with the above results, PTEN-mRNA-PGCP NP treatment markedly reduced the cell viability of androgen receptor-positive PCa LNCaP cells as well as the invasive LNCaP LN3 subclone, which are both deficient in PTEN ( Supplementary  Fig. 6a ). Cell apoptosis was also increased in LNCaP cells in the PTEN-mRNA-PGCP NP treatment group relative to empty PGCP NP or EGFP-mRNA-PGCP NP control groups ( Supplementary  Fig. 6b ). In contrast, delivery of PTEN mRNA with our PGCP NPs into normal prostate epithelial cells (PreC) or into PTEN-competent DU145 cells did not significantly affect cell viability ( Supplementary Fig. 7a ), nor was there any significant change in PI3K-AKT signalling ( Supplementary Fig. 7b ). This finding is consistent with earlier results 50 showing that PTEN +/-DU145 cells are refractory to conventional transfection with PTEN plasmid and suggests that restoration of PTEN may most effectively suppress growth and survival of tumour cells with defective PTEN expression. Similar to the results with PCa cells, PTEN-mRNA-PGCP NP treatment restored PTEN protein and growth-suppressive activity in PTEN-null MDA-MB-468 breast cancer cells, with treated cells 2000 (L2K) at a mRNA concentration of 0.5 µ g ml -1 . This high transfection activity was confirmed by confocal microscopy (Fig. 2d ), although L2K mRNA-transfected PC3 cells exhibited higher fluorescence intensity. We found similar highly effective transfection activity of EGFP-mRNA-PGCP NPs in DU145 and LNCaP cells, with > 98% and 86% efficiency at the 0.5 µ g ml -1 concentration, respectively (Supplementary Figs. 1b,c and 2b,c). While the transfection activity of our mRNA NPs was comparable to that of L2K-transfected mRNA in DU145 cells, the NP group showed significantly greater transfection efficacy relative to L2Ktransfected mRNA in LNCaP cells, especially at EGFP mRNA concentrations of 0.25 and 0.5 µ g ml -1 .
To investigate the ability of the NPs to protect mRNA from RNase degradation, we incubated EGFP-mRNA-PGCP NPs at two weight ratios of mRNA to RNase (1:1 and 1:10) for 30 min and then evaluated the transfection activity in PC3 cells. A concentration of 0.250 μ g ml -1 EGFP mRNA was used. Naked EGFP mRNA (with or without RNase incubation) complexed with L2K was used as a control. The transfection of naked EGFP mRNA (without RNase incubation) complexed with L2K showed ~85% efficiency, whereas transfection in the RNase-treated groups was drastically reduced to the level similar to that of the untreated control. In contrast, EGFP-mRNA-PGCP NPs notably maintained the integrity and activity of the mRNA at both RNase concentrations, consistently showing ~90% transfection capacity, comparable to the transfection in the absence of RNase ( Supplementary Fig. 3a,b ).
Mechanisms of cellular uptake and endosomal escape of mRNA NPs.
To evaluate the cellular uptake mechanisms and intracellular transport of mRNA NPs, we studied the transfection efficiency of EGFP-mRNA-PGCP NPs in PC3 cells pretreated with different inhibitors. NP transfection was not affected by either a caveolaemediated inhibitor (filipin) or a clathrin-mediated inhibitor (chlorpromazine). In contrast, uptake was significantly decreased from ~80% (without inhibitor) to ~40% in the presence of 5-(N-ethyl-N-isopropyl)-amiloride (EIPA), a macropinocytosis inhibitor. Transfection of mRNA NPs was also markedly decreased from ~80% (without inhibitor) to ~58% in the presence of the protonpump inhibitor bafilomycin A1 (Baf A1) 45, 46 . We further tested transfection activity using combinations of filipin, chlorpromazine or EIPA with Baf A1. Filipin+ Baf A1 and chlorpromazine+ Baf A1 exhibited low transfection efficiency similar to Baf A1 alone, whereas EIPA+ Baf A1 showed a combinatorial effect, exhibiting superior inhibition of transfection activity ( Fig. 2e ,f). These results suggest that cellular internalization of the EGFP-mRNA-PGCP NPs is partly mediated by macropinocytosis, and after entering into the cells, the NPs are able to induce a proton-sponge effect to release the cargo cytosolically. All the above inhibitors are commonly used to investigate the cellular uptake and transport pathways of NPs [44] [45] [46] . These results suggest that this combinatorial cellular uptake and endosomal escape mechanism, together with the inherent properties of mRNA, could constitute a potential advantage of this mRNA delivery system.
Functional NP delivery of PTEN mRNA to PTEN-null PCa cells in vitro.
We prepared PTEN mRNA by in vitro transcription (IVT) as previously described 47, 48 . PTEN mRNA was modified with anti-reverse cap analogue (ARCA) capping and enzymatic polyadenylation and was fully substituted with pseudouridine 5'-triphosphate (pseuodo-UTP) and 5-methylcytidine-5'-triphosphate (5′ -methyl-CTP), followed by DNase and phosphatase treatment. Substitution with pseudo-UTP and 5′ -methyl-CTP in replacement of regular UTP and CTP, respectively, was applied for reducing mRNA immunostimulation 42, 48, 49 . The PTEN mRNA was also tagged with haemagglutinin (HA) to ensure easy detection and separation from endogenous message. We first transfected PTEN showing reduced cell viability and PI3K-AKT signalling as well as induced apoptosis via PARP cleavage and Annexin V staining ( Supplementary Fig. 8a-d ). PTEN-competent MDA-MB-231 cells showed no effect on those phenotypes after PTEN-mRNA-PGCP NP treatment. Together, our results indicate the potential of PTEN-mRNA-PGCP NPs to restore the tumour-suppressor activity of PTEN in PTEN-defective cells of different tumour origins.
In vivo pharmacokinetics and biodistribution of mRNA NPs. To predict the in vivo performance of our mRNA NPs for systemic delivery, we first evaluated pharmacokinetics by administering cyanine 5 (Cy5)-tagged EGFP-mRNA (Cy5-EGFP-mRNA) NPs, prepared with two different lipid-PEGs (ceramide-PEG and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy{polyethylene glycol}] (DSPE-PEG)) into healthy BALB/c mice via tail-vein intravenous (i.v.) injection. These were compared with the pharmacokinetics of naked Cy5-labelled EGFP mRNA. The EGFP-mRNA-PGDP NPs possessed excellent physicochemical properties, with particle size and surface charge of 112.7 ± 1.3 nm and 5.22 ± 0.43 mV, respectively ( Supplementary Fig. 9a ), along with good stability in serum conditions and stable particle size over 48 h at 37 °C ( Supplementary  Fig. 9b ). Notably, the in vitro transfection efficiency in PC3 cells was > 80% at an mRNA concentration of 0.5 μ g ml -1 , as measured by GFP fluorescence, which was comparable to that observed with L2K administration of EGFP mRNA in vitro ( Supplementary  Fig. 10 ). The pharmacokinetics results showed that naked mRNA was cleared rapidly, with a dramatic decrease to ~10% after 5 min. Cy5-EGFP-mRNA-PGCP NPs slightly extended the circulation of Cy5-EGFP mRNA at various time points compared to that of naked mRNA, with a half-life of > 5 min. In contrast, Cy5-EGFP-mRNA-PGDP NPs had an even longer circulation profile, with a half-life of > 30 min. Moreover, ~30% of the Cy5-EGFP-mRNA PGDP NPs was still circulating after 60 min, while naked mRNA and Cy5-EGFP-mRNA-PGCP NPs dropped to 1% and 4%, respectively. At 240 min, 5% of the Cy5-EGFP-mRNA-PGDP NPs could still be detected ( Fig. 4a ). To evaluate the biodistribution and tumour accumulation, athymic nude mice bearing human PC3 xenograft tumours were injected with naked Cy5-EGFP mRNA or Cy5-EGFP-mRNA NPs (either PGCP or PGDP) via the tail vein. A high percentage of NPs accumulated in the spleen and liver after i.v. administration. However, most importantly, Cy5-EGFP-mRNA-PGDP NPs exhibited high tumour accumulation in the PC3 xenograft, whereas no or minimal signals in tumours were detected for naked Cy5-EGFP mRNA or Cy5-EGFP-mRNA-PGCP NPs (Fig. 4b ). We also examined the biodistribution of PGCP and PGDP NPs encapsulating Cy5-PTEN mRNA to specifically assess the distribution of PTEN mRNA in vivo. The results explicitly reproduced a similar biodistribution; Cy5-PTEN mRNA exhibited higher distribution in tumours with the PGDP NPs compared to naked Cy5-PTEN mRNA or Cy5-PTEN-mRNA-PGCP NPs ( Supplementary Fig. 11a,b ). This high tumour accumulation led us to advance this strategy into in vivo efficacy studies with tumour-bearing mice.
In vivo therapeutic efficacy and mechanism of PTEN mRNA NPs in a PCa xenograft model. To validate the in vivo therapeutic efficacy of PTEN mRNA NPs in a PCa xenograft model, we systemically (i.v. via tail vein) injected PTEN-mRNA-PGDP NPs every 3 days for six injections (Fig. 5a ) in immunocompromised athymic nude mice bearing subcutaneous PC3 xenograft tumours. Tumourbearing mice injected with PBS or EGFP-mRNA-PGDP NPs were used as controls. Both the PBS and EGFP-mRNA-PGDP NP groups showed rapid tumour growth, while PTEN-mRNA-PGDP NP treatment notably suppressed tumour growth compared to the controls (Fig. 5b,c) . The average tumour sizes rapidly increased to ~674 mm 3 and ~738 mm 3 for the mice treated with EGFP-mRNA-PGDP NPs or PBS, respectively. These tumour sizes were significantly higher compared to ~288 mm 3 for PTEN-mRNA-PGDP NP treatment at day 43 post tumour induction ( Fig. 5c ). Moreover, the average tumour weight for the PTEN-mRNA-PGDP NP treatment group was also significantly lower than that of the control groups ( Supplementary Fig. 12 ). No treatment group underwent significant changes in body weight, suggesting minimal toxicity ( Fig. 5d ).
These results demonstrate the feasibility of using systemic mRNA NP delivery to reverse the effects of tumour suppressor loss in prostate tumours in vivo.
To further understand the mechanisms underlying the therapeutic activity of PTEN-mRNA-PGDP NPs, we assessed HA-PTEN expression in tumour sections obtained on the third day after the last injection by immunohistochemistry analysis using a HA antibody. PTEN-mRNA-PGDP NP treatment resulted in HA-PTEN protein expression in tumours, whereas the PBS and EGFP-mRNA-PGDP NP controls did not show any background HA-PTEN expression ( Fig. 5e ). Next, TdT-mediated dUTP nick end labelling (TUNEL) assays of tumour sections revealed that PTEN-mRNA-PGDP NPs increased tumour cell apoptosis significantly more than either EGFP-mRNA-PGDP NPs or PBS ( Fig. 5f ). These results suggest that the effective systemic restoration and efficient expression of PTEN in tumours mediated by NP delivery of PTEN mRNA leads to enhanced tumour cell apoptosis and decreased tumour cell survival. Consequently, this approach may represent a viable treatment strategy for restoring tumour growth suppression to PCa in vivo.
In vivo therapeutic efficacy of PTEN mRNA NPs in models of advanced PCa. To validate the in vivo therapeutic efficacy of PTEN mRNA NPs in models of advanced PCa, we first established a disseminated PC3 metastatic model by injecting luciferase-tagged PC3 (PC3-luc) cells into the tail vein of immunocompromised, male athymic nude mice. Tumour metastases were detected in the lung and other organs of the mice by bioluminescence imaging (Bruker Xtreme). Four weeks post tumour challenge, we systemically (i.v. via tail vein) injected PTEN-or EGFP-mRNA-loaded PGDP NPs every 3 days for five doses (PBS was used as the control). Based on the fold change of bioluminescence of PC3-luc cells in mice, it was found that the PTEN-mRNA-PGDP NPs significantly prevented the progression of metastatic cancer when compared to the PBS-treated and EGFP-mRNA-PGDP NP-treated groups (Fig. 6a ). The quantitative analysis demonstrated a significant difference in the fold change in average radiance at the experimental end point (day 15) in the PTEN-mRNA-PGDP NP cohort compared to the PBS cohort (*P = 0.0289), as well as the PTEN-mRNA-PGDP NP versus the EGFP-mRNA-PGDP NP cohort (*P = 0.0469) ( Fig. 6b ,c, Supplementary Fig. 13a ). These results demonstrate the efficacy of the systemic delivery of PTEN mRNA-loaded NPs in a disseminated metastatic PCa model.
We also tested the mRNA NPs in a PCa bone model given that bone is the most common site of PCa metastasis 51 . We performed orthotopic, intratibial injections with the PC3-luc cells in immunocompromised, male athymic nude mice. Then we systemically injected PTEN-mRNA-PGDP NPs 5 days post tumour inoculation and every 3 days for four injections in total ( Fig. 7a ). Both the PBS and EGFP-mRNA-PGDP NP control groups demonstrated rapid tumour growth (Fig. 7b,c) . Moreover, mice receiving PTEN-mRNA-PGDP NPs, compared to PBS or EGFP-mRNA-PGDP NP treatment, showed a significant decrease in fold change in the average radiance at day 17 post tumour inoculation, which was the experimental end point (****P < 0.0001 for both comparisons; Fig. 7c , Supplementary Fig. 13b ). At the experimental end point (day 17) for the intratibial orthotopic model, cohorts that received PTEN-mRNA-PGDP NP treatment experienced a 90.7% reduction compared to cohorts that received PBS and a 85.23% reduction compared to cohorts that received EGFP-mRNA-PGDP NPs (****P < 0.0001 for both comparisons). These findings indicate the ability of PTEN-mRNA-PGDP NPs to reduce tibia tumour burden ( Fig. 7c, Supplementary Fig. 13b ). These results are further indicative of the ability of PTEN mRNA NP delivery to decrease tumour outgrowth in an orthotopic site of PCa metastasis. Notably, no treatment group showed any significant changes in body weight in both the disseminated metastatic and intratibial orthotopic PCa models, indicating the safety of this therapeutic system ( Supplementary  Fig. 14) . Additionally, quantitative real-time PCR analysis of the bone marrow lysates and immunohistochemistry analysis of the intratibial tumour sections conclusively showed expression of HA-PTEN in the bones. In contrast, no obvious expression was observed in tumours treated with either PBS or EGFP-mRNA-PGDP NPs ( Supplementary Fig. 15 ).
In vivo safety profile of PTEN mRNA NPs. To evaluate the in vivo side effects of mRNA NPs, various organs and blood serum were collected 3 days after the last injection (day 28) and at the end point (day 43) of the PCa xenograft experiment (Fig. 8a,b ). Organs were sectioned and stained with haematoxylin and eosin (H&E). We found no histological differences in the tissues from lung, heart, liver, spleen or kidney between PBS and NP treatment groups, suggesting no notable toxicity. For haematological analysis (days 28 and 43), we used appropriate assay kits to check the following parameters: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) to assess liver function; creatinine and blood urea nitrogen (BUN) to evaluate kidney activity; and troponin-1 to assess cardiac function. We found no obvious changes in these parameters in serum from mice after treatment with the mRNA NPs, further indicating negligible side effects. We also investigated whether mRNA NPs mediated any in vivo immune response in immunocompetent mice to exclude the possibility that the antitumour efficacy of PTEN mRNA NPs might be caused by an immunostimulatory effect. There was a similarly modest increase in the levels of the proinflammatory cytokine tumour necrosis factor-α (TNF-α ) for both the empty PGDP NPs and the PTEN-mRNA-PGDP NPs at 6 h post-injection, suggesting that the cytokine response may be attributable to the NPs themselves rather than the effect of encapsulated PTEN mRNA. PBS and naked PTEN mRNA stimulated minimal TNF-α responses, as expected ( Supplementary Fig. 16 ). TNF-α levels for both empty PGDP NPs and PTEN-mRNA-PGDP NPs returned to baseline PBS levels 24 h post injection, suggesting that immune stimulation (for example, TNF-α ) by the NPs themselves was transient and that the PTEN mRNA had no lasting adverse immune or inflammatory activity. In sum, our results demonstrate the effective reversal of the PTENnull phenotype in PCa and in breast cancer cells in vitro, and in vivo after systemic delivery of PTEN-mRNA-PGDP NPs. The inhibitory effect is dependent on the presence of PTEN mRNA delivered by the NP and is not mediated by nonspecific host responses to either the NPs themselves or to the introduction of other mRNA species.
Discussion
Loss and/or mutation of tumour-suppressor genes is a dominant force in tumour development and clinical resistance to a variety of therapies 52 . Reversal of the phenotype induced by loss of tumour suppressors has long proven to be an elusive goal. Two major strategies have been employed for suppressor restoration: restoring a functional copy of a given tumour-suppressor gene via transfection; and the use of small-molecule agents to reactivate tumoursuppressor function via a conformational change in the mutated molecule 53 . The latter approach has met with little success and is destined to be ineffective when the suppressor gene has been deleted. The major limitations of restoring a suppressor gene in tumours include inefficient delivery to tumour cells, poor transfection efficacy, insufficient expression and possible insertional mutagenesis. Consequently, restoring tumour-suppressor activity in cancer cells is highly challenging and requires the design of a functionally improved tumour suppressor with a unique therapeutic modality that can withstand the rigors of systemic delivery, especially in the metastatic setting where the tumour burden is widely distributed. The modified PTEN mRNA NP technology reported herein is an early example of such an approach. To our knowledge, tumour inhibition following direct systemic restoration of a tumour-suppressor gene using an mRNA delivery strategy in vivo has not been shown before. Use of a mRNA delivery system enables rapid gene expression with controlled and predictable expression kinetics, higher transfection efficiency and, most importantly) avoidance of genomic complexation and mutagenesis due to the inherent cytoplasmic and diminished nuclear expression of the desired protein 29 . In addition, we report a delivery system using a new-generation polymer-lipid hybrid NP system that provides effective i.v. delivery of the suppressor mRNA to tumour xenografts. The end result is restoration of PTEN function, as illustrated by the inhibition of both primary and advanced tumour growth, increased apoptosis and blockade of the PI3K-AKT signalling pathway. Because PTEN loss is frequent in latestage PCa, we suggest that this approach may have feasibility in this patient population. In previous reports, the most widely investigated nonviral gene delivery carriers such as polyethylenimine (PEI), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)/cholesterol liposome and the DOTAP/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) system 48, [54] [55] [56] provided only suboptimal and variable mRNA transfection efficacy (40-80%) in cancer cells and fibroblasts (for example, HeLa and NIH 3T3 cells). In addition, in PCa cells (for example, PC3) it was reported that the mRNA transfection efficacy of the PEI-mRNA complex was only 30%, although a high in vitro mRNA transfection activity in PC3 cells was found using a histidine-rich reducible polycation system 57 . Our polymer-lipid hybrid mRNA NPs prepared using a robust self-assembly strategy provided 86-98.2% mRNA transfection capacity with minimal toxicity in various PCa cell lines (for example, LNCaP, PC3 and DU145), a new standard for in vitro delivery of mRNA to tumours. Potential reasons for this effective mRNA delivery to tumours may be the relatively small size of the NPs (~120 nm), as well as their very high (95-100%) mRNA encapsulation efficiency, compact shape and good stability. Whereas a smaller particle size could be achieved with small oligonucleotides such as siRNA, it is more difficult with larger payloads such as mRNA. It is worth noting that such small NPs may more efficiently permeate the leaky tumour microvasculature and achieve greater tumour accumulation and deeper tissue penetration compared to larger NPs [58] [59] [60] [61] .
For systemic in vivo application, PEGylation of NPs is a welldocumented strategy to prevent rapid elimination from the circulation, since it reduces the interaction between NPs and serum proteins following recognition by mononuclear phagocytic systemmediated clearance mechanisms 62, 63 . Simultaneously, PEGylation could also hinder NP interactions with the target cell membrane, which may decrease tumour cell-mediated uptake. Therefore, proper dissociation of lipid-PEG molecules is necessary for optimal systemic circulation and extravasation of our mRNA NPs at the tumour site, as well as effective uptake by tumour cells. We have demonstrated that the dissociation kinetics depend on the structure of the lipid-PEG molecules in the hybrid NPs and may be controlled by the length and/or saturation of lipophilic tails 44 . In that context, DSPE-PEG exhibited a relatively slow de-PEGylation profile compared to ceramide-PEG. This effect was described earlier from our measurements of the dissociation kinetics of lipid-PEG from NPs in the presence of serum albumin, which is the most abundant plasma protein and binds with diacyl lipids 64 . Moreover, we observed a quicker release of ceramide-PEG than DSPE-PEG from NPs and found that the surface charge of the NPs changed over time after lipid-PEG dissociation. The charge of ceramide-PEG NPs rapidly increased from 2.2 to 31.4 mV in 3 h, but slowly for DSPE-PEG NPs from − 4.0 to 11.9 mV over 24 h, although both NPs were initially near neutral. This slow de-PEGylation profile conferred better pharmacokinetics, tumour biodistribution and therapeutic efficacy for DSPE-PEG NPs 44 . Thus, our hybrid mRNA NPs coated with DSPE-PEG showed higher stability, longer circulation and increased tumour accumulation compared to ceramide-PEG NPs. This results in a more efficient systemic restoration of mRNA to tumours and has implications beyond any particular tumour suppressor and cancer type. PTEN loss has been recognized for two decades as being involved in PCa progression [65] [66] [67] . Surprisingly, there has been no progress on the direct restoration of PTEN function in PTEN-null PCa cells, presumably due to the inefficient delivery and insufficient expression of PTEN at the tumour site. Recently, a secreted form of PTEN called PTEN-long that can penetrate cells has been discovered and shown to rescue PTEN function in PTEN-null U87-MG glioblastoma cells and in MDA-MB-468 breast cancer cells in vitro and in vivo 68 . Our approach is complementary to these findings and is perhaps more generalizable to a wide variety of tumour-suppressor molecules. Recent protein structure studies have reported that PTEN and PTEN-long have different properties relating to conformational change, membrane binding and substrate specificity 69 . Future studies will be necessary to explore the relative efficacy of these two approaches. It is further likely that delivery of mRNA NPs will achieve greater tumour-specific distribution than free protein.
It was also recently reported that PTEN loss promotes resistance to clinical therapy as well as T cell-mediated immunotherapy 70, 71 , suggesting that restoring functional PTEN via our PTEN mRNA NP technology could be useful in immunotherapeutic applications and in rescuing chemosensitivity in resistant tumours. Therefore, delivery of mRNA NPs also holds the potential to potentiate other therapeutic approaches 29 . Our findings provide significant support for the proof of concept that the systemic restoration of PTEN rescues PTEN function in PTEN-null PCa and effectively suppresses tumour progression with negligible side effects.
In summary, in vivo restoration of PTEN represents a new approach to PI3K-AKT pathway inhibition, with the potential to significantly improve the treatment of patients with cancer that have loss of PTEN function. Moreover, considering the strong potential of mRNA therapy and the lack of systemic studies of in vivo mRNA transfection of tumours, this study sheds light on the useful application of NP-mediated mRNA delivery for validating tumour suppressors (for example, PTEN and p53) as therapeutic targets in the treatment of cancer.
Methods

Materials.
Ester-terminated PLGA (viscosity 0.26-0.54 dl g -1 ) was purchased from Durect Corporation. Cationic ethylenediamine core-poly(amidoamine) (PAMAM) dendrimer generation 0 (G0) and Baf A1 were purchased from Sigma-Aldrich. Filipin III, chlorpromazine and EIPA were purchased from Cayman Chemicals. DSPE-PEG (molecular weight (MW) of PEG, 5,000 Da) and ceramide-PEG (MW of PEG, 2,000 Da) were obtained from Avanti Polar Lipids. L2K was purchased from Invitrogen. EGFP mRNA (modified with pseudo-UTP and 5′ -methyl-CTP) and Cy5-EGFP mRNA (modified with pseudo-UTP and 5′ -methyl-CTP) were purchased from TriLink Biotechnologies. Sequence-verified human wild-type PTEN, G129E and G129R open reading frame (ORF) were cloned into pENTR223 followed by recombination into the Gateway destination vector pHAGE (MSCV-N-Flag-HA-IRES-PURO, long terminal repeat-driven expression) using λ recombinase. pLenti CMV Puro LUC (W168) was a gift from E. Campeau (Addgene plasmid no. 17477) 72 . ViraPower Lentiviral packaging mix was purchased from Thermo Fisher Scientific. D-luciferin-K+ salt bioluminescent substrate (no. 122799) was obtained from PerkinElmer. Primary antibodies used in this work included the following: anti-PTEN (138G6), anti-pAKT-Ser473 (no. 9271), anti-p70S6K-Thr389 (108D2), anti-pFOXO3a-Ser318/321 (no. 9465), anti-pPRAS40-Thr246 (D4D2), p4E-BP1-Thr37/46 (236B4), p4E-BP1-Ser65 (no. 9451), anti-HA antibody (C29F4) and anti-PARP (no. 9542) antibodies (rabbit, Cell Signaling); anti-HA antibody (3F10) (rat, Roche); anti-HA-HRP conjugated antibody (A00169) (goat, GenScript); and anti-GFP antibody (A-6455) (rabbit, Life Technologies).
Preparation of modified PTEN mRNA. The vector carrying the ORF of PTEN was a gift from W. Sellers 73 (pSG5L HA wild-type PTEN; Addgene, no. 10750). The vector was linearized by ApaI/EcoRI digestion and purified. HA-PTEN ORF under the regulation of the T7 promoter was then amplified by PCR. The amplicons were further purified and used as templates for IVT. The modified PTEN mRNA was synthesized as described previously 47, 48 . In brief, IVT was conducted using a MEGAscript T7 kit (Ambion) with 1-2 µ g template and 7.5 mM ATP, 1.5 mM GTP, 7.5 mM 5-methyl-CTP, 7.5 mM pseudo-UTP (TriLink Biotechnologies) and 6 mM 3′ -0-Me-m 7 G(5′ )ppp(5′ )G (ARCA) (TriLink Biotechnologies). Reactions were incubated at 37 °C for 4 h, followed by Turbo DNase treatment for 15 min. 3′ poly(A)-tails were further added to IVT RNA products using a poly(A) tailing kit (Ambion). mRNA was purified by using a MEGAclear kit (Ambion), then treated with Antarctic Phosphatase (New England BioLabs) at 37 °C for 30 min, and further purified. Large-scale PTEN mRNA was custom-prepared by TriLink Biotechnologies as above (ARCA capped and enzymatically polyadenylated; fully substituted with pseudo-UTP and 5′ -methyl-CTP; DNase and phosphatase treated; silica membrane purified) using 100-150 µ g template containing the T7 promoter and HA-PTEN ORF.
Synthesis of cationic lipid compound (G0-C14).
The cationic lipid-like compound G0-C14 was synthesized from PAMAM dendrimer G0 using a ringopening reaction by reacting with 1,2 epoxytetradecane according to previously described procedures 44, 74 . Briefly, 1,2 epoxytetradecane was mixed with PAMAM dendrimer G0 at a molar ratio of 7:1, whereby substoichiometric amounts of 1,2 epoxytetradecane were added to increase the proportion of products with one less tail than the total possible for a given amine monomer. The reaction was carried out for 2 days under vigorous stirring, and the crude mixture was separated on silica with gradient elution from CH 2 Cl 2 to 75:22:3 CH 2 Cl 2 /MeOH/NH 4 OH using chromatography.
mRNA complexation ability of G0-C14 and its stability in organic solvent. To assess the mRNA complexation ability of G0-C14 and its stability in organic solvent (DMF), naked EGFP mRNA or EGFP mRNA complexed with G0-C14 (in varying weight ratios from 1 to 20) were incubated with or without DMF for 30 min. For mRNA samples in DMF, electrophoresis was run without extracting mRNA from DMF into aqueous solution. The volumes of samples were then adjusted with loading dye (Invitrogen) and run into an E-Gel 2% agarose (Invitrogen) gel for 30 min at 50 V. The Ambion Millennium markers-Formamide (Thermo Fisher Scientific) was used as a ladder. Finally, the gel was imaged under ultraviolet and the bands were analysed.
Preparation of mRNA NPs. We employed a robust, self-assembly method to prepare mRNA-encapsulated polymer-lipid hybrid NPs as previously described 44 , but with significant modification and optimization in ratios of reagents used in the NP formulation. In brief, PLGA and G0-C14 were dissolved separately in DMF at concentrations of 5 mg ml -1 and 2.5 mg ml -1 , respectively. Then, PLGA (250 µ g in 50 µ l) and G0-C14 (250 µ g in 100 µ l) were mixed at a weight ratio of 1:1 in a small glass vial. mRNA (16 µ g at 1 mg ml -1 concentration) in aqueous solution was mixed into the PLGA-G0-C14 organic solution (weight ratio of mRNA:PLGA:G0-C14 was 1:15:15) to form cationic lipid-mRNA nanocomplexes. This solution was then quickly nanoprecipitated into 10 ml of lipid-PEG (for example, ceramide-PEG or DSPE-PEG) aqueous solution (0.1 mg ml -1 concentration in DNase/RNase-free Hypure water) for ~20 s. The weight ratio of lipid-PEG to PLGA was 4:1. Upon nanoprecipitation, NPs formed instantly and were kept for 30 min at 600 r.p.m. stirring at room temperature to stabilize. The NPs were then washed three times with ice-cold Hypure water using Amicon tubes (molecular weight cut-off, 100 kDa; Millipore) to remove organic solvent and free compounds and finally concentrated into 1 ml PBS solution. The NPs were used fresh or kept at − 80 °C to use later for various in vitro and in vivo studies. The mRNA NPs were subjected to gel electrophoresis as described above to check for any leaching of unencapsulated mRNA. The NPs prepared with ceramide-PEG and DSPE-PEG were termed PGCP NPs and PGDP NPs, respectively.
Physicochemical characterization and stability of mRNA NPs in serum condition. mRNA NPs were characterized by assessing their size, surface charge and morphology. Sizes were measured by NanoSIGHT (Malvern, NS300) at 20 °C and analysed using Nanoparticle Tracking Analysis, which utilizes the properties of both light scattering and Brownian motion to determine the particle size distribution of samples in liquid suspension. 
Generation of luciferase-tagged PC3 cells. The lentiviral vector pLenti CMV
Puro LUC encoding the firefly luciferase was transfected with Virapower Lentiviral packing mix to 293T cells using L2K. After 48 h, lentiviral supernatant was collected and added into 20-40% confluent PC3 cells. Polybrene (8 μ g ml -1 ) was added during the transduction. Two days after transduction, PC3 cells were selected by puromycin at 2 μ g ml -1 concentration. Luciferase expression was analysed by immunofluorescence staining and western blotting. PC3-luc cells were maintained in media containing 1 μ g ml -1 puromycin.
In vitro cytotoxicity and transfection activity of mRNA NPs. Cells were seeded at a density of 3-5 × 10 4 cells per well on a 24-well plate and allowed to attach and grow until ~80% confluence. Cells were transfected with mRNA NPs at various mRNA concentrations (0.062, 0.125, 0.250 and 0.500 µ g ml -1 ) for 16 h followed by washing with fresh complete medium and further incubated for 24 h to check cytotoxicity as well as transfection efficiency. L2K was used as a standard transfection reagent (according to the manufacturer's protocol) to form L2K-mRNA complexes for comparison with the mRNA NPs. Cytotoxicity was measured using the Alamar Blue assay according to the manufacturer's protocol and a microplate reader (TECAN, Infinite M200 Pro). Alamar Blue is a nontoxic assay that allowed us to continuously check real-time cell proliferation. For transfection efficiency measurement, cells were collected with 25% EDTA trypsin and washed two times and resuspended in PBS followed by measuring GFP expression using flow cytometry. The percentages of GFP-positive cells were calculated, and histograms were prepared using Flowjo software.
RNase protection assay.
To test whether the NPs protected the mRNA from RNase, naked EGFP mRNA and EGFP-mRNA-PGCP NPs were incubated in RNase at two mRNA/RNase weight ratios (1:1 and 1:10) for 30 min at 37 °C, shaking at 100 r.p.m. A concentration of 0.250 μ g ml -1 EGFP mRNA was used in this study. After incubation, RNase was separated from the EGFP-mRNA-PGCP NPs and naked mRNA by washing with water via centrifugation in 100 kDa Amicon filter tubes at 1,300 RCF for 10 min. The post RNase-treated EGFP-mRNA-PGCP NPs were then diluted in media, while the naked mRNA was complexed with L2K, and the PC3 cells were then transfected as described above and incubated for 16 h. The medium was replaced and incubated for an additional 24 h. The naked EGFP mRNA and EGFP-mRNA-PGCP NPs without RNase treatment were used as negative controls. Cells were then collected to measure EGFP expression by flow cytometry and analysed using Flowjo as described above.
Mechanism of cellular uptake and endosomal escape of mRNA NPs. To determine the uptake and intracellular transport mechanism of mRNA NPs, 24-well plates were used to seed PC3 cells at an initial density of 5 × 10 4 cells per ml in 1 ml of growth medium and incubated for 24 h at 37 °C in 5% CO 2 to allow the cells to attach. The cells were then pre-incubated for 30 min in serum-free medium containing inhibitors. Filipin (1 μ g ml -1 ), chlorpromazine (10 μ g ml -1 ), EIPA (10 μ g ml -1 ) and Baf A1 (200 nM) was used to block caveolae-mediated endocytosis, clathrin-mediated endocytosis, macropinocytosis and intracellular proton-pump inhibitor effects, respectively, alone and in combination. The cells were then transfected with EGFP-mRNA-PGCP NPs at a mRNA concentration of 0.250 μ g ml -1 . After 16 h, the old medium was replaced with fresh complete medium and incubated for an additional 24 h. The cells were then collected to check EGFP expression by flow cytometry and analysed by Flowjo as described above.
Cell growth inhibition assay with PTEN mRNA NPs. Cell growth inhibition was determined by CyQUANT assay in 96-well plates. First, 3 to 5 × 10 3 cells per well per 100 μ l were seeded in 96-well plates. The next day, cells were treated with mRNA NPs or the L2K-mRNA mixture. After 72 h of incubation under standard cell culture conditions, the culture medium was removed and plates were kept at − 80 °C for > 24 h. Cells were counted using the CyQUANT kit (Life Technologies) per the manufacturer's instructions. Fluorescence measurements were made using a microplate reader with excitation at 485 nm and emission detection at 530 nm. Cell growth inhibition was also determined using a MTT bromide assay. Briefly, 3 to 5 × 10 3 cells were plated in a 96-well plate and treated with NPs the next day. After 16 h, NPs were removed and fresh medium was added. After 72 h of incubation, 10% culture volume of MTT (5 mg ml -1 ; Sigma Chemicals) was added to each well. After incubation for an additional 4 h, isopropanol-HCl solution (200 μ l) was added to each well to dissolve the cell pellets. Absorbance was determined using a 96-well SpectraMax plate reader (Molecular Devices) at 560 nm and 650 nm (background).
Apoptosis assay in vitro. Cells were seeded in 6-well plates until ~80% confluence and then treated with PTEN mRNA NPs. The next day, the NPs were removed (16 h post treatment) and kept in culture for another 24 h. The supernatant and the cell monolayer were collected, washed with PBS and processed for detection of apoptotic cells using an Annexin V-PE/7AAD apoptosis detection kit (BD Biosciences) according to the manufacturer's instructions.
Western blot assay. Protein extracts were prepared using NP-40 lysis buffer (50 mM Tris-HCl (pH 7.5), 0.5% NP-40 substitute, 150 mM NaCl and 12.5 mM NaF) supplemented with Complete Mini EDTA-free protease inhibitor tablets (Roche). Equal amounts of protein, as determined with a bicinchoninic acid protein assay kit (Pierce/Thermo Scientific) according to the manufacturer's instructions, were separated by SDS-PAGE and transferred to nitrocellulose membranes. The blots were blocked with 5% non-fat dry milk in TBST (50 mM Tris-HCl at pH 7.4 and 150 mM NaCl, and 0.1% Tween 20) and then incubated with appropriate primary antibodies. Signals were detected with horseradish peroxidase-conjugated secondary antibodies and an enhanced chemiluminescence (ECL) detection system (Amersham/GE Healthcare). When indicated, membranes were subsequently stripped for reprobing.
Immunofluorescence staining and microscopy. For immunofluorescence staining, cells were plated onto coverslips in 6-well plates and grown overnight to 60-70% confluence. Cells were washed with ice-cold PBS and fixed with 4% paraformaldehyde (Electron Microscopy Sciences) in PBS for 15 min at room temperature. Cells were then permeabilized by incubation in 0.2% Triton X-100-PBS for 8 min followed by blocking with PBS blocking buffer containing 2% normal goat serum, 2% BSA and 0.2% gelatin for 1 h at room temperature. Then, the samples were incubated in primary antibody (1:200 anti-HA rat antibody) for 1 h at room temperature, washed with PBS and incubated in goat anti-rat-Alexa Fluor 488 (Molecular Probes) at 1:500 dilution in blocking buffer for 30 min at room temperature. Finally, stained cells were washed with PBS, counterstained with 500 nM 4,6-diamidino-2-phenylindole (DAPI), and mounted on slides with Prolong Gold antifade mounting medium (Life Technologies).
Animals. Six-week-old BALB/c male normal mice were used for pharmacokinetics and immune response studies. To evaluate the biodistribution of mRNA NPs in various organs, including tumours, and to test the therapeutic efficacy of PTEN mRNA NPs to suppress tumour growth, male athymic nude mice (6 weeks old) were obtained from Charles River Laboratories. All animal studies were performed under strict regulations and pathogen-free conditions in the animal facility of the Brigham and Women's Hospital and in accordance with National Institutes of Health animal care guidelines. The animals had free access to sterile food pellets and water and were kept in the laboratory animal facility with temperature and relative humidity maintained at 23 ± 2 °C and 50 ± 20%, respectively, under a 12-h light/dark cycle. Mice were kept for at least 1 week to acclimatize them to the food and environment of the animal facility. The animal protocol was approved by the Institutional Animal Care and Use Committees at Harvard Medical School.
Pharmacokinetics study. For the in vivo pharmacokinetics study, healthy BALB/c male mice (6 weeks) were divided into three groups (n = 3 per group) and intravenously administered with the following through the tail vein at a mRNA dose of 700 µ g per kg of animal weight: (1) naked Cy5-EGFP mRNA; (2) Cy5-EGFP-mRNA-PGCP NPs; or (3) Cy5-EGFP-mRNA-PGDP NPs. At various predetermined time intervals (0, 5, 15, 30, 60, 120, 180 and 240 min), retro-orbital vein blood was withdrawn using a heparin-coated capillary tube, and the wound was gently pressed for a few seconds to stop the bleeding. Fluorescence intensity of Cy5 was measured at emission and excitation wavelengths of 640 and 670 nm, respectively, using a microplate reader. Pharmacokinetics was calculated by calculating the percentage of Cy5-EGFP mRNA in blood at various time periods, normalized with the initial (0 min) time point.
PC3 xenograft tumour model preparation.
To prepare the PC3 xenograft tumour mouse model, approximately 4 × 10 6 cells in 100 µ l of culture medium mixed with 100 µ l of matrigel (BD Biosciences) were implanted subcutaneously on the right flank of 6-week-old male athymic nude mice. Mice were monitored for tumour growth every other day according to the animal protocol.
Biodistribution of mRNA NPs in the PCa xenograft tumour model. For the biodistribution study, PC3 xenograft-bearing male athymic nude mice received an i.v. injection of naked Cy5-EGFP mRNA, Cy5-EGFP-mRNA-PGCP NPs or Cy5-EGFP-mRNA-PGDP NPs via the tail vein at a mRNA dose of 700 µ g per kg of animal weight. Twenty-four hours later, organs and tumours were collected and imaged with an IVIS Lumina III In Vivo Imaging System (Perkin Elmer).
To evaluate the in vivo biodistribution specifically for PTEN mRNA in the tumour xenograft model, Cy5-PTEN mRNA was prepared by substituting 25% pseduo-UTP with Cy5-UTP when conducting IVT reactions. The Cy5-PTEN mRNA and its PGCP and PGDP NPs were then injected (i.v. via the tail vein) for the biodistribution analysis as described above.
In vivo therapeutic efficacy of PTEN mRNA NPs in the PCa xenograft tumour model. For in vivo therapeutic efficacy, PGDP NPs were used as a delivery system for PTEN mRNA and EGFP mRNA as a negative control. PC3 xenograft-bearing athymic nude mice were treated when the tumours were first palpable. The mice were randomly divided into three groups to receive the following: (1) PBS (n = 7);
(2) EGFP-mRNA-PGDP NPs (n = 9); or (3) PTEN-mRNA-PGDP NPs (n = 8). Mice were injected with the above samples via the tail vein at a mRNA dose of 700 µ g per kg of animal weight at days 10, 13, 16, 19, 22 and 25 after tumour induction. Tumour size was measured using a caliper every 3 days until day 43, and the average tumour volume (mm 3 ) was calculated as: ½(length × width × height). The body weights of the mice were also determined. At day 28 (3 days after the last injection), mice (1 mouse for PBS and 2 mice for each EGFP-mRNA-PGDP NP and PTEN-mRNA-PGDP NP group) were selected randomly for collection of tumours to monitor PTEN expression and tumour cell apoptosis, and various organs to examine in vivo toxicity. The mice were imaged at day 35, and the image backgrounds were removed using Adobe Photoshop software. At day 43, mice were killed and various organs (lung, heart, liver, kidney and spleen) were collected to assess toxicity by immunohistochemical analysis. Blood serum was also collected at the two time points of days 28 and 43 for haematological assays.
In vivo therapeutic efficacy of PTEN mRNA NPs in advanced PCa models.
To assess the in vivo therapeutic efficacy of PTEN mRNA NPs in advanced PCa, we prepared two different mouse models of advanced PCa: (1) an experimental metastasis model employing i.v. inoculation of PC3-luc PCa cells; and (2) a bone colonization of intratibial inoculation of PC3-luc cells as an orthotopic model of PCa-established metastases. For the experimental metastatic PCa model, 2.5 × 10 6 PC3-luc cells in 100 µ l of PBS were implanted through i.v. tail vein injection into immunocompromised, male athymic nude mice (78 in total). Two weeks after implantation, mice were monitored for tumour growth every 3 days using an In-Vivo Xtreme imaging system (Bruker) for initial screening of mice exhibiting PC3-luc dissemination for treatments. Four weeks post tumour inoculation, 24 mice (incidence rate of ~30%) with i.v. disseminated PCa, detected using the In-Vivo Xtreme imaging system after mice were injected intraperitoneally with 150 mg per kg luciferin substrate (PerkinElmer, catalogue no. 122799), were randomly divided into three groups (n = 8 per treatment group), which received the following treatments: PBS, EGFP-mRNA-PGDP NPs or PTEN-mRNA-PGDP NPs. Treatments were performed via i.v. tail vein injection at a mRNA dose of 700 µ g per kg of animal weight. Initial treatment was performed at day 28 post tumour inoculation, followed by another four injections at days 31, 34, 37 and 40 every 3 days (in total, five injections). Tumour images were also obtained every 3 days from the day of initial treatment (at day 28 post tumour inoculation) until day 43 post tumour inoculation using the In-Vivo Xtreme imaging system with a charge-coupled device camera (exposure time 30 s, binning of 1, field of vision of 19 cm, f/stop of 1.10 and no filter). Regions of interest (ROI) were quantified as average radiance (photon per s per cm 2 per sr) using the Bruker MI SE software, and the fold change of ROI in each measurement (at days 28, 31, 34, 37, 40 and 43) was normalized with the ROI at the day of treatment initiation (at day 28) and plotted using GraphPad software (version 7). To prepare the intratibial orthotopic PCa model, immunocompromised, male athymic nude mice were anaesthetized with isoflurane, and 5 × 10 4 PC3-luc cells in 10 µ l of PBS were injected into the right tibia of each mouse (72 mice in total). After the cells were given time to establish in the bone (5 days post tumour inoculation in the bone), the mice with efficient intratibial injections and successful tumour establishment (36 mice with 50% success rate screened through an established visual image and similar photon counts) were randomly divided into the above three groups (n = 12 mice per treatment group) and treatments were initiated. Treatments were performed via i.v. tail vein injection at a mRNA dose of 700 µ g per kg of animal weight. Initial treatment was performed at day 5 post tumour inoculation, followed by another three injections at day 8, 11 and 14 in every 3 days (in total, four injections). Tumour images were also obtained every 3 days from the day of initial treatment (at day 5 post tumour inoculation) until day 17 post tumour inoculation using the In-Vivo Xtreme imaging system as mentioned above. ROI were quantified as average radiance (photon per s per cm 2 per sr) using the Bruker MI SE software, and the fold change of ROI in each measurement (at days 5, 8, 11, 14 and 17) was normalized with the ROI at the day of treatment initiation (at day 5) and plotted using GraphPad software (version 7). The body weights of the mice were also determined every 3 days and plotted using GraphPad software (version 7). At day 17 of the intratibial tumour study (the terminal time point), specimens of the 12 mice of each group were randomly divided into 2 sets to perform immunohistochemistry (n = 6 mice) and quantitative real-time PCR (n = 6 mice) assays to detect PTEN expression in the bone with tumour tissues.
Immunohistochemical staining to detect in vivo PTEN expression. The expression of HA-PTEN protein in tumour tissue sections was assessed by immunohistochemistry. Sections (5-µ m thick) were obtained from tumours treated with PBS, PTEN-mRNA-PGDP NPs or EGFP-mRNA-PGDP NPs. Paraffin-embedded sections were deparaffinized, rehydrated and washed in distilled water. Samples were then incubated for 20 min with 0.3% hydrogen peroxide at room temperature to quench endogenous peroxidase activity followed by antigen retrieval in citrate buffer (pH 6.0) using a microwave for 10 min (2 times, each time 5 min). After washing with PBS (pH 7.4), the samples were treated with an Avidin/Biotin Blocking kit (Vector) to quench endogenous biotin and then immersed in blocking buffer (1% BSA, 5% normal goat serum) for 60 min. Tissue sections were then incubated with primary rabbit anti-HA antibody at 4 °C overnight in a humidified chamber. After rinsing with PBS, the samples were incubated with biotinylated secondary antibody for 30 min at room temperature, followed by incubation with the avidin-biotin-horseradish peroxidase complex (ABC kit, Vector Laboratories). Staining was developed using a diaminobenzidine peroxidase substrate kit (Impact DAB, Vector Laboratories) for 3 min. Sections were then counterstained with haematoxylin (Sigma), dehydrated and mounted.
Quantitative real-time PCR assay. Total RNA was extracted from bone marrow collected from mouse tibiae using a RNeasy mini kit (Qiagen). RNA was then reverse transcribed into complementary DNA using a high capacity cDNA reverse transcription kit (Thermo Fisher Scientific) and quantitative real-time PCR was conducted with SYBR Green master mix (Thermo Fisher Scientific). HA-PTEN mRNA expression was normalized to beta actin. TUNEL apoptosis assay. Tumours were extracted and fixed in formalin, embedded in paraffin and sectioned at a thickness of 5 µ m. Tumour cell apoptosis was determined by TUNEL assay (In Situ Cell Death Detection Kit, TMR red; Roche, no. 12-156-792-910) according to the manufacturer's protocol. DAPI stain was used to assess the total cell number.
In vivo toxicity evaluation: haematological examination, histology and immune response. To evaluate in the vivo toxicity, blood was drawn retro-orbitally and serum was isolated from PC3 xenograft athymic nude mice 3 days after the final injection (day 28) and at the end of the efficacy experiment (day 43). AST, ALT, BUN, creatinine and troponin-1 were measured using assay kits for AST (BioVision), ALT and creatinine (Cayman Chemical), BUN (Arbor Assays) and troponin-1 (Life Diagnostics) according to the manufacturers' protocols. For histological examination, various organs (lung, heart, liver, kidney and spleen) were also collected 3 days after the final NP injection (day 28) and at the end point of the experiment (day 43). The organs were then fixed with 4% paraformaldehyde and embedded in paraffin followed by sectioning (3-4 µ m) and staining with H&E. The slides were assessed using an EVOS Cell Imaging System (Thermo Fisher Scientific). Next, to check the immunological response, male Balb/c immunocompetent male mice (n = 3) received an i.v. injection of PBS, naked PTEN mRNA (700 µ g mRNA per kg), empty PGDP NPs or PTEN-mRNA-PGDP NPs. Six or 24 hours post injection, serum samples were collected and processed to measure the representative cytokine (TNF-α ) by enzymelinked immunosorbent assay (ELISA) (Affymetric eBioscience) according to the manufacturer's protocol.
Statistical analysis. All graphs were prepared using GraphPad Prism 7 software, and statistical analyses were also carried out using GraphPad Prism 7 software to perform one-way analysis of variance (ANOVA), two-sided t-tests or Mann-Whitney tests. Mann-Whitney tests were performed for experiments for which the data were determined to be non-parametric by the normality test [75] [76] [77] (that is, for both disseminated metastatic and intratibial orthotopic experiments). All experiments were performed in triplicate unless otherwise stated. Error bars indicate the standard deviation (s.d.) unless otherwise noted specifically as the standard error of the mean (s.e.m.). A P value < 0.05 was considered statistically significant, whereby all significant values shown in various figures are indicated as follows: *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. 
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Data exclusions
Describe any data exclusions. No data were excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization was done with the automated software "Random Sequence Generator", https://www.random.org/sequences/.
The mice in the intravenous model system had been randomized to receive treatment after robust evidence of metastatic tumour colonization by a priori detection of visible bioluminescense imaging signal. For the IV metastasis study, 2.5×106 PC3-luc cells in 100 μl of PBS were implanted through i.v. tail vein injection into 7 weeks old male athymic nude mice (n=78 in total). Two weeks after implantation, mice were monitored for tumour growth every three days using an In-vivo Xtreme imaging system (Bruker) for initial screening to randomize for treatments. Finally, 4 weeks post tumor inoculation, 24 mice (success rate of ~30%) with i.v. disseminated PCa (n=8 per group) were randomly divided into the three treatment groups: PBS, EGFP-mRNA-PGDP NP and PTEN-mRNA-PGDP NP.
For the randomization of the intratibial injection of PC3-luc cells in immunocompromised male athymic nude mice (n= 72 mice), we confirmed tumour development at day 5 post cancer cell inoculation by both visual bioluminescent images and priori photon-counts assessment before initiation of treatment. Five days post tumour inoculation (50% of the mice successfully developed tumours). The successful tumour models (n=36 mice) were randomly divided into the above three treatment groups (n=12 mice per treatment group) and treatments were initiated at day 5 post-cancer cell inoculation.
To prepare the PC3-xenograft tumour mice model, about 4×10^6 cells in 100 μL of culture medium mixed with 100 μL of matrigel (BD Biosciences) were implanted subcutaneously on the right flank of 6-week-old male athymic nude mice. Mice were monitored for tumour growth every other day according to the animal protocol. PC3 xenograft-bearing athymic nude mice were treated when the tumours were first palpable. The mice were randomly divided into the above three treatment groups.
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Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was used for animal studies.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Bruker MI SE, Graph Pad Prism (Version 7), Microsoft Excel
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All materials are commercially available.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Primary antibodies used in this work included the following: anti-PTEN (138G6), anti-p-Akt-ser473 (#9271), anti-p-70S6K-Thr389 (108D2), anti-p-FOXO3a-Ser318/321 (#9465), anti-p-PARS40-Thr246 (D4D2), p-4E-BP1-Thr37/46 (236B4), p-4E-BP1-Ser65 (#9451) and anti-PARP (#9542) antibodies (rabbit, Cell Signaling); anti-HA antibody (3F10) (rat, Roche); anti-HA-HRP conjugated antibody (A00169) (goat, GenScript); Anti-GFP antibody (A-6455) (rabbit, Life Technologies). b. Describe the method of cell line authentication used. All cells were authenticated (using the "DDC Biomedical" or "Genetica DNA Laboratories" cell-line authentication test) and checked for mycoplasma contamination before in vitro cell experiments and in vivo xenograft tumour-model preparation.
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c. Report whether the cell lines were tested for mycoplasma contamination.
All cells were tested for mycoplasma contamination, by using both DAPI staining and PCR detection.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
6-week-old BALB/c male normal mice were used for pharmacokinetics (PK) and immune-response studies. 7-8-week-old male athymic nude mice were used for biodistribution and therapeutic-efficacy studies.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study did not involve human research participants.
